Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Hepatitis delta virus (HDV) infection results in more severe and even fulminant form of hepatitis B in co-infected cases.
This study was designed to estimate the prevalence of anti-HDV positivity and the associated risk factors in patients with
chronic hepatitis B virus infection in Tajikistan. In this cross-sectional study a total of 440 consecutive patients with chronic
hepatitis B virus (HBV) infection attending the Institute Gastroenterology of the Ministry of Health, Republic of Tajikistan
clinic from 2014 to 2017 were included. We performed test for HDV serum marker, using commercially available enzymelinked
immunosorbent assay kit. Patients were split into two groups according to their HDV antibody status as HDV positive
or negative. The collected data were coded, and the statistical analyses were conducted. 440 patients with various forms of
chronic HBV-related liver diseases enrolled in the study. 200 (45.5%) patients were carrier for HBV. 196 (44.5%) patients had
chronic active hepatitis and 44 (10%) patients suffered from cirrhosis. Anti-HDV was demonstrated in 75 patients (17%). The
prevalence of HDV was 7%, 16.3% and 65.9% in carriers, patients with chronic active hepatitis and cirrhosis, respectively. HDV
infection is still an important public health problem in Tajikistan and appears a major cause of progression of liver disease
induced by HBV.
Recent Publications:
1. Husa P, Linhartova A, Nemecek V, Husova L. Hepatitis D. Acta Virol. 2005;49(4):219-25.
2. Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology.
1984;86(6):1417-20.
3. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C,Bonino F, Verme G. Immunofluorescence detection ofnew
antigen-antibody system (delta/anti-delta) associatedto hepatitis B virus in liver and in serum of HBsAg carriers. Gut.
1977;18(12):997-1003.
4. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011Apr19
5. Celen MK, Ayaz C, Hosoglu S, Geyik MF, Ulug M. Antihepatitis delta virus seroprevalence and risk factors in patients
with hepatitis B in Southeast Turkey. Saudi Med J 2006; Vol. 27 (5): 617-620.
Biography
Ramazanova Zamira is of age 63 years from Institute of Gastroenterology of the Republic of Tajikistan. She works at the Department of virology, Institute of Gastroenterology of the Republic of Tajikistan. She has published more than 30 papers in reputed journals.